

## Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Odan-Benzoydamine 1.5 mg/ml Solution (DIN 02463105) manufactured by Odan Laboratories Ltd. and pms-Benzoydamine 1.5 mg/ml Solution (DIN 02239537) manufactured by Pharmascience Inc., Pharixia 1.5 mg/ml Solution (DIN 02229777) manufactured by Pendopharm Inc. was added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Odan Laboratories Ltd. has advised Alberta Blue Cross that the shortage Odan-Benzoydamine 1.5 mg/ml Solution (DIN 02463105) has been resolved.

As a result, Pharixia 1.5 mg/ml Solution (DIN 02229777) will no longer be considered a temporary benefit for the *ADBL* **after July 28, 2022**. The above grouping was removed from the Critical Supply Product List on **June 28, 2022**.

## Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Admelog 100 unit/ml Injection (DIN 02469901) manufactured by Sanofi – Aventis, Humalog 100 unit/ml Injection (DIN 02229704) manufactured by Eli Lilly Canada Inc., will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **June 21, 2022**.

As of **June 21, 2022**, all claims for Humalog 100 unit/ml Injection (DIN 02229704) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php).

If this situation continues to be a long-term matter, then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

*continued next page*

## PHARMACY BENEFACT

---

*continued from previous page*

Due to the unavailability of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944) manufactured by Sandoz Canada Inc., Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376) manufactured by Juno Pharmaceuticals Corp. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **June 29, 2022**.

As of June 29, 2022, all claims for Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [ab.bluecross.ca/providers/pharmacy-home.php](https://ab.bluecross.ca/providers/pharmacy-home.php).

If this situation continues to be a long-term matter, then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

---

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://ab.bluecross.ca/providers/pharmacy-home.php)

